Core Viewpoint - The company Baiotai (688177) has received the acceptance notice from the National Medical Products Administration for its investigational drug BAT5906, a recombinant humanized monoclonal antibody [1] Group 1: Drug Information - BAT5906 is an innovative drug developed and produced by the company, classified as an IgG1 full-length antibody with a molecular weight of 149KDa [1] - The drug specifically binds to human VEGF-A165, inhibiting neovascularization [1] - In vitro models of angiogenesis show that BAT5906 can block the binding of VEGF to its corresponding receptors, suppressing endothelial cell proliferation and new blood vessel formation [1]

Group 1: Suspension of Trading - Zhongwei Company is planning to acquire the controlling stake of Hangzhou Zhonggui Electronic Technology through a share issuance and raise matching funds, resulting in a stock suspension [1] - Nandu Power's controlling shareholder has terminated the plan for a change in control, leading to the resumption of trading [1] Group 2: Shareholding and Buybacks - Sichuan Road and Bridge has been targeted by Zhongyou Insurance, increasing its shareholding to 5% [2] - Xizang Pharmaceutical plans to repurchase shares worth between 170 million to 200 million yuan, with a maximum repurchase price of 55 yuan per share [3] Group 3: Investments and Operations - Visionox intends to sign the "Investment Cooperation Agreement II" to advance the Hefei 8.6-generation AMOLED production line project, with a second-phase capital of 9.443 billion yuan [4] - Jiangnan New Materials plans to invest approximately 300 million yuan in the development and industrialization of high-end copper-based core materials in the Yingtan High-tech Industrial Development Zone [4] - Haitian Flavoring and Food will maintain a cash dividend ratio of no less than 80% annually for the next three years (2025-2027) [5] - Tianfeng Securities has signed a supplementary agreement to extend the maturity of its original 4 billion yuan subordinated debt by one year with its controlling shareholder Hongtai Group [5] - Qibin Group's subsidiary plans to establish a new energy company in Shenzhen with an investment of 600 million yuan [6] - Jiangsu Guoxin's subsidiary plans to increase capital by 1.8 billion yuan to advance its Phase III 2×100 MW expansion project [7] - Fosun Pharma's subsidiary has signed a "Cooperation and Option Agreement" with ClavisBio, potentially receiving up to 363 million USD in payments [7] - Baotai's application for marketing authorization of the injection of Vilasitamab (BAT5906) has been accepted [8] - Zhengye Technology has signed sales contracts for X-ray equipment totaling 120 million yuan [9] - Jinqilin's CRH380D train brake pads have passed small-scale trials [10]

Core Viewpoint - The company Baiotai has received approval from the National Medical Products Administration for the marketing authorization application of its investigational drug, BAT5906, which is indicated for neovascular (wet) age-related macular degeneration (nAMD) [1] Group 1 - BAT5906 is a recombinant humanized monoclonal antibody innovative drug developed and produced by the company [1] - The drug is an IgG1 type full-length antibody with a molecular weight of 149KDa [1] - BAT5906 specifically binds to human VEGF-A165 to inhibit neovascularization [1]

Group 1 - Shandong Zhanggu received administrative regulatory measures from the Shandong Securities Regulatory Commission due to issues related to related party transactions, information disclosure violations, improper use of raised funds, and non-compliance in corporate governance [1] - Nanjing Pharmaceutical plans to invest 120 million yuan to establish a medical device investment company, holding a 59.9% stake, which will focus on investing in Ningbo Jiangfeng Biological Information Technology Co., Ltd. [2] - ST Mingjia's stock will be suspended for one day on December 19 due to the implementation of its restructuring plan [3] Group 2 - Baotai's application for the marketing authorization of BAT5906 has been accepted by the National Medical Products Administration [4] - Nanhua Futures has set the final price for its H-share public offering at 12 HKD per share, with trading expected to begin on December 22 [5] - Visionox plans to invest 3.918 billion yuan in the second phase of capital contribution to Hefei Guoxian, increasing its shareholding to 37.73% [6] Group 3 - Dafu Technology intends to transfer 49% of its stake in Dasheng Graphite at a base price of 206 million yuan [7] - Aorite has passed the GMP compliance inspection for its production lines [8] - CICC announced a cash dividend distribution of 434 million yuan for the first half of 2025, with a dividend of 0.09 yuan per share [9][10] Group 4 - Sichuan Road and Bridge received a stake increase from Zhongyou Insurance, raising its holding to 5% [11] - Jinhua Co. plans to apply for a comprehensive credit line of 185 million yuan from Guangfa Bank [12] - Huicheng Environmental Protection's private placement has been approved by the China Securities Regulatory Commission [13] Group 5 - Junwei Electronics has established a joint venture with Placo New Materials in Hong Kong [14] - Huaye Fragrance appointed Gao Ming as the deputy general manager [15] - Yongmaotai received a government subsidy of 17.2242 million yuan, accounting for 45.92% of its net profit for the last audited fiscal year [16] Group 6 - Haitian Flavoring plans a special dividend of 3 yuan per 10 shares, totaling 1.754 billion yuan [17] - Haizheng Pharmaceutical's subsidiary received a new veterinary drug registration certificate [18] - Hailianxun's share swap merger with Hangzhou Qilun has been approved by the CSRC [19] Group 7 - ST Shuangcheng's injection of bortezomib ANDA has been approved by the US FDA [20] - Tibet Pharmaceutical plans to repurchase shares worth between 170 million and 200 million yuan [21] - Jiayuan Technology has set a preliminary transfer price of 39.93 yuan per share for its inquiry transfer [22] Group 8 - Jiemai Technology has invested in Beijing Critical Field Technology Co., Ltd. [23] - Zotye Auto plans to reach a settlement with SAIC Transmission Company regarding a contract dispute [24] - Xianju Pharmaceutical's application for the registration of estradiol tablets has been accepted [25] Group 9 - Xinya Electronics has established a subsidiary focused on urban rail transit technology [26] - Southern Precision has received a total credit line of 179 million yuan from ICBC and CCB [27] - Ningbo Construction's subsidiary won a 747 million yuan engineering project [28] Group 10 - Whirlpool plans to sign a supplementary agreement regarding component procurement with Whirlpool Corporation [29] - Haixiang New Materials intends to sell part of its under-construction factory for 41.3774 million yuan [30] - Menohua's subsidiary's atorvastatin calcium raw material drug application has been approved [31] Group 11 - Beilu Pharmaceutical plans to use up to 500 million yuan of idle funds for cash management [32] - Jiangnan New Materials plans to invest 300 million yuan in a high-end copper-based core material project [33] - Jinqilin's CRH380D train brake pads have passed small-scale trials [34] Group 12 - China Chemical signed contracts worth 352.569 billion yuan from January to November 2025 [35] - Guanghuan New Network plans to apply for an additional credit line of 300 million yuan [36] - Zhengye Technology signed a 120 million yuan equipment procurement contract [38] Group 13 - Xinno's subcutaneous injection of secukinumab has achieved primary endpoint success in its Phase III clinical trial [39] - Qinglong Pipe Industry signed a procurement contract worth 55.2671 million yuan [40]

证券代码： 688177 证券简称： 百奥泰 公告编号：2025-070 百奥泰生物制药股份有限公司 关于维拉西塔单抗注射液（BAT5906） 上市许可申请获得受理的公告 受理号：CXSS2500142 适应症：新生血管性（湿性）年龄相关性黄斑变性（nAMD） 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 百奥泰生物制药股份有限公司（以下简称"百奥泰"或"公司"）于近日收 到国家药品监督管理局（以下简称"国家药监局"或"中国 NMPA"）核准签发 的关于公司在研药品维拉西塔单抗注射液（以下简称"BAT5906"）药品上市 许可申请的《受理通知书》。 BAT5906 经审评审批通过后可获发药品批准证书并可投入生产、销售， 因为审评审批的办结时间无法预估，所以本次获得药品上市许可申请受理通 知书对公司近期业绩不会产生影响。 一、 《受理通知书》基本情况 药品名称：维拉西塔单抗注射液 注册分类：治疗用生物制品 1 类 剂型：注射剂 规格：16mg/0.2ml 申请事项：境内生产药品注册上市许可 结论：根据《中华人民共和国行政许 ...

Core Viewpoint - The company Baiotai has received the acceptance notice from the National Medical Products Administration for the marketing authorization application of its investigational drug, Vela-sitran monoclonal antibody injection [1] Group 1: Product Information - Vela-sitran is classified as a Class 1 biological product for the treatment of neovascular (wet) age-related macular degeneration (nAMD) [1] - BAT5906 is an innovative drug developed and produced by Baiotai, characterized as a recombinant humanized monoclonal antibody [1] - The drug is an IgG1 type full-length antibody with a molecular weight of 149 kDa, specifically binding to human VEGF-A165 to inhibit neovascularization [1]

Core Viewpoint - The company Baiotai (688177.SH) has received a notice of acceptance from the National Medical Products Administration for its investigational drug, BAT5906, which is a monoclonal antibody injection aimed at treating diseases related to abnormal blood vessel growth [1] Group 1: Drug Information - BAT5906 is a recombinant humanized monoclonal antibody classified as a Class 1 therapeutic biological product [1] - The drug specifically binds to human VEGF-A165, inhibiting neovascularization [1] - In vitro models show that BAT5906 can block the binding of VEGF to its receptors, suppressing endothelial cell proliferation and new blood vessel formation [1] Group 2: Pharmacokinetics and Safety - In animal studies, BAT5906 demonstrated a longer half-life in the vitreous of monkeys compared to the Fab fragment structure of Ranibizumab, potentially allowing for longer injection intervals in clinical settings [1] - The drug does not trigger antibody-dependent cellular cytotoxicity (ADCC), suggesting a lower incidence of systemic adverse reactions and potentially safer clinical applications [1] Group 3: Regulatory Status and Impact - Upon approval, BAT5906 will receive a drug approval certificate and can be produced and marketed [1] - The timeline for the review and approval process is uncertain, indicating that the acceptance notice will not have an immediate impact on the company's recent performance [1]

Core Viewpoint - The company Baiotai (688177) has received the acceptance notice from the National Medical Products Administration for its investigational drug BAT5906, which is aimed at treating neovascular (wet) age-related macular degeneration (nAMD) [1] Group 1 - The drug BAT5906 is an injectable monoclonal antibody [1] - The application for BAT5906's market approval has been officially accepted [1] - The targeted indication for BAT5906 is neovascular (wet) age-related macular degeneration (nAMD) [1]

Core Viewpoint - The company Baiotai (688177.SH) has received a notice of acceptance from the National Medical Products Administration for its investigational drug, BAT5906, which is a monoclonal antibody injection aimed at treating diseases related to abnormal blood vessel growth [1] Group 1: Drug Information - BAT5906 is a recombinant humanized monoclonal antibody, classified as a Class 1 therapeutic biological product [1] - The drug specifically binds to human VEGF-A165, inhibiting neovascularization [1] - In vitro models show that BAT5906 can block the binding of VEGF to its receptors, suppressing endothelial cell proliferation and new blood vessel formation [1] Group 2: Safety and Efficacy - In animal studies, BAT5906 demonstrated a longer half-life in the vitreous of monkeys compared to the Fab fragment structure of Ranibizumab, potentially allowing for longer injection intervals in clinical use [1] - The drug does not trigger antibody-dependent cell-mediated cytotoxicity (ADCC), suggesting a lower incidence of systemic adverse reactions and potentially safer clinical applications [1] Group 3: Regulatory Status - Upon approval, BAT5906 will receive a drug approval certificate and can be produced and marketed [1] - The timeline for the review and approval process is uncertain, indicating that the acceptance notice will not impact the company's short-term performance [1]

Core Insights - The article highlights the strategic positioning of Baotai in the competitive landscape of the biopharmaceutical industry in Guangzhou, particularly in the Huangpu District, where it is surrounded by major players like Kangfang Biotech and BeiGene [1] Group 1: Company Development - Baotai has maintained a steady pace of launching 1-2 products annually since its IPO in 2020, with five products currently on the market, including three biosimilars that have entered the medical insurance system [2] - The company has established a strong market position in the biosimilar sector, with its core products being the first domestic biosimilars in their respective categories [2] - Baotai's strategy is twofold: short-term reliance on biosimilars for cash flow and survival, while long-term focus on innovative drugs to build core competitiveness [2] Group 2: Innovation and Challenges - Baotai is developing BAT8006, a promising drug for platinum-resistant ovarian cancer, which is currently in Phase III clinical trials and is among the leading candidates in domestic research [3] - The company reported a revenue of 684 million yuan for the first three quarters of the year, a year-on-year increase of 17.57%, while its net profit loss narrowed by 38.72% [4] - Despite the progress, Baotai faces challenges in market competition for biosimilars and difficulties in the hospital entry of innovative drugs due to their non-inclusion in medical insurance [4] Group 3: Policy Support and Market Access - The Guangzhou Municipal Health Commission has introduced measures to facilitate the entry of innovative drugs into hospitals, requiring medical institutions to discuss the inclusion of these drugs within one month of the product directory release [5] - Baotai's products have been included in the first batch of innovative drug lists in Huangpu District, which offers financial incentives for medical institutions to procure these products [7] - The introduction of the "Puhui Kang" insurance product aims to enhance access to local innovative drugs, with a reimbursement rate of up to 60% for residents [7][8] Group 4: Talent and Infrastructure - The competition in the biopharmaceutical industry is fundamentally a competition for talent, necessitating a supportive ecosystem for research and living conditions [6] - Transportation issues and housing shortages on the International Bio Island pose challenges for attracting and retaining talent [6] - The development of a comprehensive industrial and living ecosystem is crucial for fostering a sense of belonging among employees and ensuring long-term commitment [6]